YAYukiko Akahori

Yukiko Akahori

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yukiko Akahori has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Broad permissiveness of mammalian nectin-4 orthologs for morbilliviruses: a notable exception in dolphin nectin-4

    by Mizuki Tominaga, Fumio Seki, Hiroki Nagata, Ayumu Hyodo, Yukiko Akahori, Yuki Kitai, Hiroshi Katoh, Makoto Takeda

    Morbilliviruses utilize signalling lymphocytic activation molecule (SLAM) and nectin-4 as their major cellular receptors and exhibit distinct host specificities despite sharing common receptor usage. While species-specific differences in SLAM have been extensively investigated, the contribution of nectin-4 to morbillivirus host range remains poorly understood because nectin-4 is highly conserved among mammals. Here, we systematically compared the receptor activities of nectin-4 orthologs from human, dolphin, bat, dog and seal for representative morbilliviruses, including measles virus (MV), cetacean morbillivirus (CeMV), canine distemper virus (CDV), phocine distemper virus (PDV) and Myotis bat morbillivirus (MBaMV). Cell–cell fusion, virus infection and plaque assays demonstrated that most nectin-4 orthologs efficiently supported infection by all tested viruses. In contrast, dolphin nectin-4 exhibited markedly reduced receptor activity for MV, PDV and MBaMV, while remaining fully functional for CeMV and CDV. This phenotype was consistently observed with multiple clinical MV isolates. Mutational analyses identified amino acid residue 63 as a key determinant of this receptor specificity. Substitution of glutamic acid at position 63 in dolphin nectin-4 with glycine restored MV receptor activity to a level comparable to that of human nectin-4. These findings demonstrate that nectin-4 is generally a broadly permissive morbillivirus receptor but that specific amino acid differences can substantially influence receptor usage. Our results indicate that receptor compatibility contributes to morbillivirus host range and cross-species transmission while being insufficient on its own to fully explain viral host specificity.

  • Open Access

    Coordinated interactions among Nipah virus N, P and M proteins drive formation of distinct inclusion bodies

    by Mitsuki Yasukochi, Mika Hosogi, Yuki Kitai, Yukiko Akahori, Akihide Ryo, Makoto Takeda, Hiroshi Katoh

    Nipah virus (NiV), a highly pathogenic zoonotic paramyxovirus, forms two distinct types of membrane-less organelles called inclusion bodies (IBs): cytosolic IBs, which serve as sites of viral RNA synthesis, and those beneath the plasma membrane (IB-PMs), which function in viral particle assembly and budding. We identified the essential domains of the NiV nucleocapsid (N) and phospho (P) proteins required for the formation of cytosolic IB-like structures with liquid-like properties. Dual-site interactions between the N- and C-terminal regions of the N and P proteins were necessary for generating these liquid organelles. In contrast, the matrix protein, along with the N and P proteins, was indispensable for the formation of IB-PM-like structures with low internal fluidity. These findings demonstrate that NiV employs specific protein–protein interactions to generate spatially and functionally distinct IBs, providing new insight into the molecular mechanisms governing viral RNA synthesis and particle formation.


  • Open Access

    Changes in ORF4 of HCoV-229E under different culture conditions

    by Yuki Kitai, Shohei Kojima, Aikeda Aishajiang, Miyuki Kawase, Oshi Watanabe, Haruka Yabukami, Rina Hashimoto, Yukiko Akahori, Hiroshi Katoh, Kazuo Takayama, et al.

    The genome of human coronavirus 229E (HCoV-229E), a causative agent of human respiratory infections, encodes a unique accessory gene, ORF4. Analysis of laboratory strains and clinical specimens has suggested that HCoV-229E acquires truncating mutations in ORF4 under standard laboratory culture conditions. This study confirmed that HCoV-229E from patients with acute respiratory infections harboured a full-length ORF4 (219 amino acids). In contrast, virus stocks derived from the same patients and passaged in conventional cultured cells [LLC-MK2, human embryonic fibroblast (HEF); HEF, HeLa] exhibited truncated ORF4 of various lengths, such as 168, 143 and 16 amino acids. However, when these virus stocks were propagated in human bronchial/tracheal epithelial cells (HBTECs) cultured at the air–liquid interface (ALI), the full-length ORF4 was selected and stably maintained throughout a prolonged observation period. These findings highlight the importance of ORF4 in patients and under physiologically relevant conditions, and the HBTEC-ALI culture system is valuable for analyzing the native properties of HCoV-229E with an intact full-length ORF4.


  • Open Access

    Structural and molecular properties of mumps virus inclusion bodies

    by Hiroshi Katoh, Ryuichi Kimura, Tsuyoshi Sekizuka, Kohei Matsuoka, Mika Hosogi, Yuki Kitai, Yukiko Akahori, Fumihiro Kato, Michiyo Kataoka, Hirotaka Kobayashi, et al.

    Viral RNA synthesis of mononegaviruses occurs in cytoplasmic membraneless organelles called inclusion bodies (IBs). Here, we report that IBs of mumps virus (MuV), which is the causative agent of mumps and belongs to the family Paramyxoviridae , displayed liquid organelle properties formed by liquid-liquid phase separation. Super-resolution microscopic analysis of MuV IBs demonstrated that nucleocapsid and phospho (P)-proteins formed a cage-like structure and that the viral polymerase adopted a reticular pattern and colocalized with viral RNAs. In addition, we characterized host RNAs localized in MuV IBs by a spatial transcriptome analysis, and found that RNAs containing G-quadruplex motif sequences (G4-RNAs) were concentrated. An in vitro phase separation assay showed that the G4-RNAs interacted with the P protein and enhanced condensation in P droplets. Together, our data show that MuV generates IBs with a characteristic cage-like structure and host G4-RNAs play an important role in forming MuV IBs.


  • Open Access

    Antibacterial effects of Kampo products against pneumonia causative bacteria

    by Yukiko Akahori, Yusuke Hashimoto, Kenichi Shizuno, Mitsuaki Nagasawa

    Community-acquired pneumonia is caused primarily by bacterial infection. For years, antibiotic treatment has been the standard of care for patients with bacterial pneumonia, although the emergence of antimicrobial-resistant strains is recognized as a global health issue. The traditional herbal medicine Kampo has a long history of clinical use and is relatively safe in treating various diseases. However, the antimicrobial effects of Kampo products against pneumonia-causative bacteria remain largely uncharacterized. In this study, we investigated the bacteriological efficacy of 11 Kampo products against bacteria commonly associated with pneumonia. Sho-saiko-To (9), Sho-seiryu-To (19), Chikujo-untan-To (91) and Shin’i-seihai-To (104) inhibited the growth of S. pneumoniae serotype 3, a highly virulent strain that causes severe pneumonia. Also, the growth of S. pneumoniae serotype 1, another highly virulent strain, was suppressed by treatment with Sho-saiko-To (9), Chikujo-untan-To (91), and Shin’i-seihai-To (104). Minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) against these strains ranged from 6.25–50 mg/mL and 12.5–25 mg/mL, respectively. Furthermore, Sho-saiko-To (9), Chikujo-untan-To (91), and Shin’i-seihai-To (104) suppressed the growth of antibiotic-resistant S. pneumoniae isolates. Additionally, Sho-saiko-To (9) and Shin’i-seihai-To (104) showed growth inhibition activity against Staphylococcus aureus, another causative agent for pneumonia, with MIC ranging from 6.25–12.5 mg/mL. These results suggest that some Kampo products have antimicrobial effects against S. pneumoniae and S. aureus, and that Sho-saiko-To (9) and Shin’i-seihai-To (104) are promising medicines for treating pneumonia caused by S. pneumoniae and S. aureus infection.